Biochemistry & Physiology: Open Access
Open Access

Biography

Upon completion of his Ph D degree in Biophysical Chemistry at California Institute of Technology in 1972, he joined UCSD as a NIH Postdoctoral Fellow to carry out pioneer work on general ligand affinity chromatography. In 1976, he studied enzymology and biochemical genetic at the National Institute of Health and in 1981, he was appointed as a faculty member and director of the Andrology Laboratory at the University of British Columbia. During the last two decades, he has created numerous monoclonal antibodies for diagnostic and therapeutic applications in human health care, including RP215 and GHR106 for potential use as anti-cancer drugs.

Research Interest

Research and Development of Antibody-Based Anti-Cancer Drugs

- RP215 monoclonal antibody was shown to recognize specifically a carbohydrate-associated epitope located on the variable regions of cancer cell expressed immunoglobulins, designated in general as CA215.

- Structural elucidation of carbohydrate-associated epitope in CA215 which is recognized by RP215 monoclonal antibody (Mab)

- Humanizations of RP215 Mab for preclinical studies

- Generations of Rat anti-idiotype Mabs as candidates for the development of anti-cancer vaccines in humans

- Establishment of an Anti-GnRH receptor Mab, GHR106, as a substitute of short-acting GnRH analogs for antibody-based anti-cancer drugs, as well as preclinical studies.

- Elucidation of mechanisms of action for RP215 and GHR106 as antibody-based anti-cancer drugs.

- Elucidation of a carbohydrate-associated epitope recognized by RP215 monoclonal antibody.

Certificate

Global Speakers in the subject

Global Experts in the subject